The answer depends heavily on which treatment you mean. IV ketamine and Spravato often have very different insurance pathways.
| Treatment | FDA status for psychiatric treatment | Typical insurance picture |
|---|---|---|
| IV ketamine | Ketamine is not FDA-approved for psychiatric disorders. | Frequently self-pay. Some providers may offer superbills or discuss possible out-of-network reimbursement. |
| Spravato (esketamine) | FDA-approved for specified depressive indications. | Many plans have coverage or prior-authorization criteria, but approval and out-of-pocket cost are member-specific. |
| At-home compounded ketamine | Compounded ketamine products are not FDA-approved psychiatric treatments. | Often self-pay; reimbursement policies vary by program and plan. |
FDA states that ketamine is not approved for any psychiatric disorder, while Spravato is an FDA-approved esketamine nasal spray with a REMS program and required clinical monitoring. FDA
Even when an insurer has a Spravato coverage pathway, that does not mean every member pays the same amount or automatically qualifies. Your diagnosis, prior treatment history, network status, deductible, copay or coinsurance, and prior authorization can all affect what you actually pay.
Aetna publishes a commercial medical policy for Spravato that requires precertification and clinical criteria. This is useful evidence that a coverage pathway exists, but it is not a guarantee of benefits for any specific Aetna member.
Source: Aetna Clinical Policy Bulletin 0950.
Sources: Keta Medical Center · Being Health · NY Ketamine Infusions.
Answer 13 questions about insurance, budget, treatment preference, location, and desired clinical support. Ketamine Match will rank options from our NYC-focused provider dataset.
Show my matches